[Pubmed] Autologous CD19/BCMA CAR-T cell therapy for myasthenia gravis: Advancing care for those with severe disease
Posté : 12 avr. 2026 12:00
Med. 2026 Apr 10;7(4):101036. doi: 10.1016/j.medj.2026.101036.
ABSTRACT
Ruan and colleagues report that dual-target CD19/BCMA CAR-T cell therapy produced marked clinical improvement in highly refractory myasthenia gravis, with steroid discontinuation and minimal toxicity. Beyond symptom control, deep immune profiling revealed sustained B-cell depletion, reduced autoantibodies, and systemic immune reprogramming toward a less inflammatory state.
PMID:41966710 | DOI:10.1016/j.medj.2026.101036
Source: https://pubmed.ncbi.nlm.nih.gov/4196671 ... t6+133c1fe